The current study suggests that pharmacologic inhibitors of TRPV4 can reduce the production of proinflammatory cytokines, restore vascular endothelial cell function, and decrease sepsis-associated hyperinflammatory response and mortality in the septic rat (124). This evidence concerns the gene TRPV4 and Sepsis.